FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence

Ana Blanca, Maria J. Requena, Jose Alvarez, Liang Cheng, Rodolfo Montironi, Maria R. Raspollini, Carlos Reymundo, Antonio Lopez-Beltran

Research output: Contribution to journalArticle

10 Scopus citations


Aim: To assess the diagnostic performance of FGFR3 and Cyclin D3 urinary protein levels in detecting bladder cancer recurrence. Patients & methods: Urine of 321 patients in follow-up for bladder cancer and 150 non-neoplastic urine controls was included. Cytology, cystoscopy and FGFR3 and Cyclin D3 expression by western blot were performed. Results: One hundred ten (34.3%) patients had evidence of tumor recurrence. The sensitivity and specificity of cytology/cystoscopy was 80 and 84%, and for FGFR3/Cyclin D3 was of 73 and 90%. Conclusion: Combined urinary FGFR3/Cyclin D3 expression shows improved detection rates for bladder cancer recurrence with high specificity and sensitivity, and within the same range of detection shown by cystoscopy, therefore supporting its potential use as noninvasive diagnostic biomarker for bladder cancer recurrence.

Original languageEnglish (US)
Pages (from-to)243-253
Number of pages11
JournalBiomarkers in Medicine
Issue number3
StatePublished - Mar 1 2016


  • bladder cancer
  • cyclin D3
  • diagnosis
  • FGFR3
  • urine
  • western blot

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Fingerprint Dive into the research topics of 'FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence'. Together they form a unique fingerprint.

  • Cite this

    Blanca, A., Requena, M. J., Alvarez, J., Cheng, L., Montironi, R., Raspollini, M. R., Reymundo, C., & Lopez-Beltran, A. (2016). FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. Biomarkers in Medicine, 10(3), 243-253. https://doi.org/10.2217/bmm.15.120